Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.
<h4>Background</h4>Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphomas (PEL). PEL cell lines infected with KSHV, but negative for Epstein-Barr virus have a tumorigenic potential in non-obese diabetic/severe combined immunodeficient mice and r...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24250827/?tool=EBI |
| _version_ | 1818575057904992256 |
|---|---|
| author | Hiba El Hajj Jihane Ali Akram Ghantous Dana Hodroj Ahmad Daher Kazem Zibara Chloé Journo Zaher Otrock Ghazi Zaatari Renaud Mahieux Marwan El Sabban Ali Bazarbachi Raghida Abou Merhi |
| author_facet | Hiba El Hajj Jihane Ali Akram Ghantous Dana Hodroj Ahmad Daher Kazem Zibara Chloé Journo Zaher Otrock Ghazi Zaatari Renaud Mahieux Marwan El Sabban Ali Bazarbachi Raghida Abou Merhi |
| author_sort | Hiba El Hajj |
| collection | DOAJ |
| description | <h4>Background</h4>Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphomas (PEL). PEL cell lines infected with KSHV, but negative for Epstein-Barr virus have a tumorigenic potential in non-obese diabetic/severe combined immunodeficient mice and result in efficient engraftment and formation of malignant ascites with notable abdominal distension, consistent with the clinical manifestations of PEL in humans.<h4>Methodology/principal findings</h4>Using this preclinical mouse model, we demonstrate that the combination of arsenic trioxide and interferon-alpha (IFN) inhibits proliferation, induces apoptosis and downregulates the latent viral transcripts LANA-1, v-FLIP and v-Cyc in PEL cells derived from malignant ascites. Furthermore, this combination decreases the peritoneal volume and synergistically increases survival of PEL mice.<h4>Conclusion/significance</h4>These results provide a promising rationale for the therapeutic use of arsenic/IFN in PEL patients. |
| first_indexed | 2024-12-15T00:35:11Z |
| format | Article |
| id | doaj.art-82a3ce35772b42f6be4136d67223f89e |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-15T00:35:11Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-82a3ce35772b42f6be4136d67223f89e2022-12-21T22:41:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01811e7947410.1371/journal.pone.0079474Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas.Hiba El HajjJihane AliAkram GhantousDana HodrojAhmad DaherKazem ZibaraChloé JournoZaher OtrockGhazi ZaatariRenaud MahieuxMarwan El SabbanAli BazarbachiRaghida Abou Merhi<h4>Background</h4>Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphomas (PEL). PEL cell lines infected with KSHV, but negative for Epstein-Barr virus have a tumorigenic potential in non-obese diabetic/severe combined immunodeficient mice and result in efficient engraftment and formation of malignant ascites with notable abdominal distension, consistent with the clinical manifestations of PEL in humans.<h4>Methodology/principal findings</h4>Using this preclinical mouse model, we demonstrate that the combination of arsenic trioxide and interferon-alpha (IFN) inhibits proliferation, induces apoptosis and downregulates the latent viral transcripts LANA-1, v-FLIP and v-Cyc in PEL cells derived from malignant ascites. Furthermore, this combination decreases the peritoneal volume and synergistically increases survival of PEL mice.<h4>Conclusion/significance</h4>These results provide a promising rationale for the therapeutic use of arsenic/IFN in PEL patients.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24250827/?tool=EBI |
| spellingShingle | Hiba El Hajj Jihane Ali Akram Ghantous Dana Hodroj Ahmad Daher Kazem Zibara Chloé Journo Zaher Otrock Ghazi Zaatari Renaud Mahieux Marwan El Sabban Ali Bazarbachi Raghida Abou Merhi Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas. PLoS ONE |
| title | Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas. |
| title_full | Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas. |
| title_fullStr | Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas. |
| title_full_unstemmed | Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas. |
| title_short | Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas. |
| title_sort | combination of arsenic and interferon α inhibits expression of kshv latent transcripts and synergistically improves survival of mice with primary effusion lymphomas |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24250827/?tool=EBI |
| work_keys_str_mv | AT hibaelhajj combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT jihaneali combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT akramghantous combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT danahodroj combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT ahmaddaher combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT kazemzibara combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT chloejourno combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT zaherotrock combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT ghazizaatari combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT renaudmahieux combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT marwanelsabban combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT alibazarbachi combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas AT raghidaaboumerhi combinationofarsenicandinterferonainhibitsexpressionofkshvlatenttranscriptsandsynergisticallyimprovessurvivalofmicewithprimaryeffusionlymphomas |